Dysfunction in Biological Technology

VIVUS Reports First Quarter 2009 Financial Results and Highlights

... 3 Trial of Avanafil for Treatment of Erectile dysfunction - In February 2009, we announced that we had ... evaluate avanafil for the treatment of erectile dysfunction in men with diabetes, one of the most common ... and avanafil for the treatment of erectile dysfunction are proceeding as planned and we look forward to ...

New Discoveries on a Fingertip Test for Screening Silent Heart Disease Promising Results of Recent Clinical Studies to be Presented during the 2009 American College of Cardiology Conference, March 29th - April 1st in Orlando

... Number: 1036-264 Abstract Title: Vascular dysfunction Measured by Digital Thermal Monitoring Strongly ... Number: 1040-102 Abstract Title: Vascular dysfunction Measured by Digital Thermal Reactivity Is ... of Oxidized LDL Biomarkers, Persistent Vascular dysfunction Measured by Fingertip Digital Thermal Monitoring ...

International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCool's New Investigational UroCool System

... Post-Operative Incontinence and Erectile dysfunction Urinary incontinence and erectile dysfunction are very common side effects following open or ... many men experience some degree of erectile dysfunction following radical prostatectomy, depending on a ...

Cardium's InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study

... Post-Operative Incontinence and Erectile dysfunction Urinary incontinence and erectile dysfunction are very common side effects following open or ... many men experience some degree of erectile dysfunction following radical prostatectomy, depending on a ...

Medivation Presents New Data on Dimebon's Novel Mechanism of Action

... suggest that mitochondrial damage and synapse dysfunction are early cellular events in Alzheimer's ... and progression. Similarly, mitochondrial dysfunction has been linked in the published literature to ... Dimebon's effect on improving mitochondrial dysfunction has been confirmed previously in the independent ...

FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML

... edema (2%, 1%), congestive heart failure/cardiac dysfunction (0%, 4%), pericardial effusion (1%, 2%), ... edema (2%, 4%), congestive heart failure/cardiac dysfunction (2%, 0%), pericardial effusion (1%, ... Bleeding Events: Dasatinib caused platelet dysfunction in vitro and thrombocytopenia in humans. Severe ...

Amarin Announces Initiation of Cardiovascular Development Strategy

... targeting the vascular system, endothelial dysfunction and vascular re-modeling. Dr. Declan Doogan, ... (LDL) cholesterol. Endothelial dysfunction is a physiological dysfunction of normal biochemical processes carried out by ...

New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain

... combination tablet reduces opioid-induced bowel dysfunction in patients with chronic severe pain compared to ... of bowel dysfunction. Opioid-induced bowel dysfunction encompasses a number of symptoms; of these, ... naloxone combination reduces opioid-induced bowel dysfunction in patients with severe chronic pain, presented ...

Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)

... promise in the treatment of female sexual dysfunction (FSD). These small molecule agents are specific ... in this underserved market." About Female Sexual dysfunction (FSD) There are an estimated 40 million women in ... as a component of female sexual dysfunction (FSD), is characterized as a persistent absence ...

Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program

... drug candidate for the treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD) from King Pharmaceuticals Inc. (NYSE: KG ... Medical Association, JAMA, titled, "Sexual dysfunction in the United States: Prevalence and Predictors," ...

Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery

... Gleevec. Severe congestive heart failure and left ventricular dysfunction have occasionally been reported. Most of the patients with reported ... HES and cardiac involvement, cases of cardiogenic shock/left ventricular dysfunction have been associated with the initiation of imatinib therapy. The ...

Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment

... ongoing Phase III programmes in premature ejaculation and erectile dysfunction as well as strengthening the Plethora balance sheet to facilitate ... Technologies, Inc., which markets products for the treatment of erectile dysfunction (ED) to urology clinics through a US-based specialty sales team. The ...

Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001

... TSX: SHQ), to jointly develop AT-1001, Alba's lead inhibitor of barrier dysfunction in various gastrointestinal ("GI") disorders. Shire will receive rights to ... acute and chronic." About AT-1001 AT-1001 is an inhibitor of barrier dysfunction that has been shown to block intestinal permeability and the genesis of ...

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007

... the Company's drug under development for the treatment of erectile dysfunction (ED) and female sexual dysfunction (FSD). Cost reimbursement revenue from King Pharmaceuticals, Inc. (King) ...

EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimer's Disease

... EnVivo presented its findings. EVP-6124 is EnVivo's novel alpha-7 nicotinic acetylcholine receptor agonist currently in development for cognitive dysfunction associated with Alzheimer's disease and schizophrenia. "EVP-6124 appears to be safe and was well tolerated over a month of dosing," ...

Novel gene found for dilated cardiomyopathy

... 21 issue of the Journal of the American College of Cardiology , which goes online July 13. "Our study indicates that variants in ANKRD1 result in dysfunction of the contraction apparatus and signaling machinery of the heart the method by which cells communicate to influence heart function," says Jeffrey ...

Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial

... purification device that absorbs endotoxin from the bloodstream, when added to conventional therapy, significantly improved hemodynamics and organ dysfunction and reduced 28-day mortality in patients with severe sepsis and septic shock. The article entitled "Early Use of Polymyxin B Hemoperfusion in ...

New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the World's Leading Bioenergetics Researchers

... Webinars, initiating a series of wet lab workshops is a natural evolution. The demand for cellular bioenergetics information keeps mounting as dysfunction of the mitochondria, the powerhouse of the cell, is being implicated in cancer, ageing, obesity, diabetes, cardiovascular disease and toxicology," ...

NeurogesX Receives European Commission Approval for Qutenza(TM)

... Fee Act (PDUFA) date of August 16, 2009. About Neuropathic Pain Neuropathic pain is a type of chronic pain that results from injury to, or dysfunction of, nerves in the central or peripheral nervous systems. Peripheral neuropathic pain is an inappropriate sensation of pain that results when injured ...

NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting

... and PDN cases and matched controls. About Neuropathic Pain Neuropathic pain is a type of chronic pain that results from injury to, or dysfunction of, nerves in the central or peripheral nervous systems. Peripheral neuropathic pain is an inappropriate sensation of pain that results when injured ...

NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union

... for one month ending April 20, 2009. About Neuropathic Pain Neuropathic pain is a type of chronic pain that results from injury to, or dysfunction of, nerves in the central or peripheral nervous systems. Peripheral neuropathic pain is an inappropriate sensation of pain that results when injured ...

BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA

... skeletal dysplasia, short stature, and joint abnormalities, which limit mobility and endurance. Malformation of the thorax as well as macrophage dysfunction in the lung likely impairs respiratory function and contributes to sinopulmonary infections. Odontoid dysplasia and ligamentous laxity can commonly ...

Implicit Licenses Clinical Stage Antibody Program From Lilly

... Injury Acute lung injury (ALI) is a severe inflammatory disease which can rapidly progress to acute respiratory distress syndrome, multi-organ dysfunction and death. The incidence of this disorder is estimated at around 200,000 cases per annum in the US and is responsible for over 75,000 deaths -- more ...

Sirion Therapeutics Partners With Advanced Vision Research (TheraTears(R)) to Promote Products for Retinal and Meibomian Gland Health

... D, green tea extract and tocotrienol (vitamin E). Meibomitis is inflammation of the meibomian glands that is a precursor to meibomian gland dysfunction (MGD), which is a cause of evaporative dry eye and is associated with ocular rosacea. Meibomitis is an incapacitating condition characterized by ...

Victhom announces the filing of a patent application to address sudden unexplained death in epilepsy (SUDEP)

... this add-on therapy, we believe existing devices would not only be able to treat seizures but also prevent SUDEP that would result from respiratory dysfunction of failure", said Mr. Kameli. He further said: "The body of knowledge in post mortem analysis of these deaths suggests that abnormal respiratory ...

The Holtorf Medical Group and Yan Center for Corrective & Cosmetic Surgery Tap 5W Public Relations

... hormone replacement and optimization for women and men, as well as chronic fatigue syndrome, fibromyalgia, adrenal insufficiency, thyroid dysfunction and complex endocrine dysfunction. www.HoltorfMed.com About The Yan Center for Corrective & Cosmetic Surgery The YAN Center for ...

Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant

... endpoint, claudication onset time, also did not show a difference. Addition of Vitamin C to 6R-BH4 did not improve efficacy on PWT. Endothelial dysfunction evaluated by peripheral arterial tonometry in a subset of patients did not show a significant benefit with 6R-BH4. Urinary protein excretion did not ...

Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients

... products should be administered at the minimum concentration available and the minimum rate of infusion practicable. While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IGIV products, those containing sucrose as a stabilizer accounted ...

OmegaGenesis Announces Angiogenesis Application Collaboration

... supplement natural human body management and re-enable where some natural processes have stopped or diminished. These diminished capabilities lead to dysfunction of human body. Our approach provides for early and pre-disease intervention in most cases," said Mr. Raza, CEO of OmegaGenesis. "Our ...

Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit

... another potential cardiovascular risk marker. Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 diabetes, a disease affecting almost 7 million patients in the United States. The Company is also developing alagebrium, a proposed ...

Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries

... 70% of radical prostatectomies are performed robotically. Post-Operative Incontinence and Erectile Dysfunction Urinary incontinence and erectile dysfunction are very common side effects following open or robotic radical prostatectomy. Temporary loss of bladder control occurs in most men. While most ...

Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting

... (carboxy-methyllysine), another potential cardiovascular risk marker. Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 diabetes, a disease affecting almost 7 million patients in the United States. The Company is also developing alagebrium, a proposed ...

Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference

... (carboxy-methyllysine), another potential cardiovascular risk marker. Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 Diabetes. The Company is also developing alagebrium, a proposed breaker of advanced glycation endproducts (AGEs) for the treatment of ...

Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association

... another potential cardiovascular risk marker. Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 diabetes, a disease affecting almost 7 million patients in the United States. The Company is also developing alagebrium, a proposed ...

FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c

... Ranexa does not reduce heart rate or blood pressure and, unlike long acting nitrates, Ranexa can be prescribed for patients taking oral erectile dysfunction treatments. "This important FDA action allows the benefits of Ranexa to be extended to more patients. The new labeling clearly describes the ...

Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast

... they are damaged, erectile function is, too. Put simply, preserving the cavernous nerves preserves sexual potency. There are treatments for erectile dysfunction resulting from radical prostatectomies but every patient, of course, wants to retain natural sexual function after prostate surgery . The ...

The human brain minimizes energy expenditure and integrates gravity in to the action plan

... the brain plans movements by integrating biological and environmental constraints and the method may be of potential value for understanding motor dysfunction and guiding subsequent rehabilitation programs. Moreover, it opens the prospect of studying brain functions by a cooperative interaction of ...

Arbios Sells HepatAssist Bioartificial Liver System to HepaLife Technologies, Inc.

... of patients suffering from cirrhosis due to chronic liver disease and who are hospitalized with acute complications due to worsening liver dysfunction and portal hypertension. The SEPET(TM) device is a sterile, disposable cartridge containing microporous hollow fibers with proprietary permeability ...

Synvista Therapeutics Posts Letter to Stockholders on Web Site

... another potential cardiovascular risk marker. Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 Diabetes, a disease affecting almost 7 million patients in the United States. The Company is also developing alagebrium, a proposed ...

A Better Tomorrow Treatment Center Inc., Forterus Inc.'s Behavioral Healthcare Subsidiary, is the First in the Nation to Offer DNA-Customized Treatment for Individuals with a Genetic Predisposition for Addictive Behavior

... president, adding that roughly a third of the world's addicts are genetically predisposed to addiction because of genetic causes involving the dysfunction of their dopamine receptors. "This doesn't mean they will automatically become addicts," Menz continued. "It just means they are more susceptible ...